205 related articles for article (PubMed ID: 34056865)
1. Copeptin as a predictive marker of incident heart failure.
Schill F; Timpka S; Nilsson PM; Melander O; Enhörning S
ESC Heart Fail; 2021 Aug; 8(4):3180-3188. PubMed ID: 34056865
[TBL] [Abstract][Full Text] [Related]
2. Copeptin predicts coronary artery disease cardiovascular and total mortality.
Tasevska I; Enhörning S; Persson M; Nilsson PM; Melander O
Heart; 2016 Jan; 102(2):127-32. PubMed ID: 26661323
[TBL] [Abstract][Full Text] [Related]
3. Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.
Wannamethee SG; Welsh P; Lennon L; Papacosta O; Whincup PH; Sattar N
Diabetologia; 2016 Sep; 59(9):1904-12. PubMed ID: 27312697
[TBL] [Abstract][Full Text] [Related]
4. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study.
Wannamethee SG; Welsh P; Whincup PH; Lennon L; Papacosta O; Sattar N
Eur J Heart Fail; 2014 Jan; 16(1):25-32. PubMed ID: 23901058
[TBL] [Abstract][Full Text] [Related]
5. Copeptin is an independent predictor of diabetic heart disease and death.
Enhörning S; Hedblad B; Nilsson PM; Engström G; Melander O
Am Heart J; 2015 Apr; 169(4):549-56.e1. PubMed ID: 25819862
[TBL] [Abstract][Full Text] [Related]
6. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
[No Abstract] [Full Text] [Related]
7. Plasma copeptin as a predictor of kidney disease.
Enhörning S; Christensson A; Melander O
Nephrol Dial Transplant; 2019 Jan; 34(1):74-82. PubMed ID: 29471407
[TBL] [Abstract][Full Text] [Related]
8. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
[TBL] [Abstract][Full Text] [Related]
9. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study.
Winther JA; Brynildsen J; Høiseth AD; Strand H; Følling I; Christensen G; Nygård S; Røsjø H; Omland T
Respir Res; 2017 Nov; 18(1):184. PubMed ID: 29100503
[TBL] [Abstract][Full Text] [Related]
11. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Velho G; Ragot S; El Boustany R; Saulnier PJ; Fraty M; Mohammedi K; Fumeron F; Potier L; Marre M; Hadjadj S; Roussel R
Cardiovasc Diabetol; 2018 Aug; 17(1):110. PubMed ID: 30071874
[TBL] [Abstract][Full Text] [Related]
12. Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study.
de Simone G; Devereux RB; Roman MJ; Chinali M; Barac A; Panza JA; Lee ET; Galloway JM; Howard BV
Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):285-91. PubMed ID: 21940153
[TBL] [Abstract][Full Text] [Related]
13. Copeptin is associated with mortality in elderly people.
Smaradottir MI; Andersen K; Gudnason V; Näsman P; Rydén L; Mellbin LG
Eur J Clin Invest; 2021 Jul; 51(7):e13516. PubMed ID: 33569762
[TBL] [Abstract][Full Text] [Related]
14. Copeptin as a biomarker in heart failure.
Balling L; Gustafsson F
Biomark Med; 2014; 8(6):841-54. PubMed ID: 25224940
[TBL] [Abstract][Full Text] [Related]
15. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.
Miller WL; Hartman KA; Grill DE; Struck J; Bergmann A; Jaffe AS
Heart; 2012 Mar; 98(5):389-94. PubMed ID: 22194151
[TBL] [Abstract][Full Text] [Related]
16. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort.
Enhörning S; Bankir L; Bouby N; Struck J; Hedblad B; Persson M; Morgenthaler NG; Nilsson PM; Melander O
Int J Obes (Lond); 2013 Apr; 37(4):598-603. PubMed ID: 22614056
[TBL] [Abstract][Full Text] [Related]
17. Utility of copeptin for predicting long-term clinical outcomes in patients with heart failure.
Yoshikawa Y; Shiomi H; Kuwahara K; Sowa N; Yaku H; Yamashita Y; Tazaki J; Imai M; Kato T; Saito N; Shizuta S; Ono K; Kimura T
J Cardiol; 2019 May; 73(5):379-385. PubMed ID: 30591319
[TBL] [Abstract][Full Text] [Related]
18. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
19. Prognostic performance of copeptin among patients with acute decompensated heart failure.
Ozmen C; Deveci OS; Tepe O; Yesildas C; Ünal İ; Yıldız İ; Eker Akıllı R; Deniz A; Demir M; Kanadaşı M; Usal A
Acta Cardiol; 2021 Oct; 76(8):842-851. PubMed ID: 32666903
[TBL] [Abstract][Full Text] [Related]
20. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction.
Pozsonyi Z; Förhécz Z; Gombos T; Karádi I; Jánoskuti L; Prohászka Z
Heart Lung Circ; 2015 Apr; 24(4):359-67. PubMed ID: 25618448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
